Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/05/2019 11/06/2019 11/07/2019 11/08/2019 11/11/2019 Date
294(c) 295.9(c) 296(c) 297.4(c) 297.95(c) Last
1 797 039 1 503 033 1 340 138 983 149 1 025 570 Volume
-1.47% +0.65% +0.03% +0.47% +0.18% Change
More quotes
Financials (CHF)
Sales 2019 61 835 M
EBIT 2019 22 068 M
Net income 2019 14 578 M
Debt 2019 2 632 M
Yield 2019 3,09%
Sales 2020 63 242 M
EBIT 2020 22 459 M
Net income 2020 15 131 M
Finance 2020 3 531 M
Yield 2020 3,24%
P/E ratio 2019 17,9x
P/E ratio 2020 17,1x
EV / Sales2019 4,13x
EV / Sales2020 3,94x
Capitalization 253 B
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists... 
Sector
Pharmaceuticals
Calendar
11/11 | 08:00amSpecial Situation
More about the company
Surperformance© ratings of Roche Holding AG
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING AG
08:15aCHUGAI PHARMACEUTICAL : Files a New Drug Application for Satralizumab for NMOSD ..
AQ
08:14aROCHE : Genentech's Gazyva in Combination With Standard of Care, More Than Doubl..
AQ
08:14aPTC THERAPEUTICS : Risdiplam Pivotal SUNFISH Study Demonstrates Statistically Si..
AQ
01:03aRoche's Gazyva (obinutuzumab), in combination with standard of care, more tha..
GL
01:01aGENENTECH : 's Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in Peop..
BU
01:00aRoche's risdiplam meets primary endpoint in pivotal SUNFISH trial in people w..
GL
11/09GENENTECH : 's Gazyva (obinutuzumab), in Combination With Standard of Care, More..
BU
11/07HARMONY® TEST : The first non-invasive prenatal test approved by Health Canada
AQ
11/06GENENTECH : to Present New Data Highlighting Breadth of Hematology Portfolio and..
BU
11/06Roche to present new data highlighting breadth of haematology portfolio and p..
GL
11/06Biogen Adding Ophthalmology Biosimilars in Deal With Samsung Bioepis
DJ
11/05REMINDER : Invitation to Roche's live audio webcast on Gazyva in lupus nephritis..
PU
11/04CHUGAI PHARMACEUTICAL : Hemlibra Launched for Hemophiia A with Inhibitors in Tai..
AQ
11/04REMINDER : Invitation to Roche's Virtual Early Drug Development pRED Event 2019
PU
11/04Healthineers forecasts growth on demand for hospital equipment
RE
More news
News in other languages on ROCHE HOLDING AG
06:45aNeue Hoffnung für Muskelschwund-Patienten - Roche-Mittel wirkt in Studie
04:30aRoche revendique des succès pour deux produits candidats
03:44aRoche erhöht die Schlagzahl - Zwei Erfolgsmeldungen aus der Pipeline
03:37aROCHE : données positive dans l'atrophie musculaire spinale
02:53aROCHE : données de phase II positives pour Gazyva
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sector news : Pharmaceuticals - NEC
03:44pMERCK AND : Gets Conditional European Commission Approval for Ebola Vaccine
DJ
10:57aGLOBAL MARKETS LIVE : Tencent, Alibaba, Boeing, Apple…
09:42aALLERGAN : Form 8.3 -
DJ
09:13aJ&J'S JANSSEN : Tremfya Meets Main Endpoints in Psoriatic Arthritis Studies
DJ
08:35aANDREW WITTY : UnitedHealth Group Names Andrew Witty as President
DJ
More sector news : Pharmaceuticals - NEC
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 311,68  CHF
Last Close Price 295,90  CHF
Spread / Highest target 20,3%
Spread / Average Target 5,33%
Spread / Lowest Target -24,0%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG22.19%254 722
JOHNSON & JOHNSON3.06%344 670
MERCK AND COMPANY9.40%211 953
PFIZER-15.12%208 023
NOVARTIS17.78%198 320
NOVO NORDISK AS30.58%133 015